Liver Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are 19 years of age or older
- People who have been diagnosed through a tissue sample (biopsy) with breast cancer that has spread to other parts of the body or has grown locally to a point where surgery or radiation to remove it fully is not possible
- People who have liver metastases (cancer that has spread to the liver) where the treating doctor believes that assessing how well treatment is working using bone scans or standard CT scans would be difficult
- People who may or may not have tumour areas that can be measured on scans, according to standard research measurement guidelines (called RECIST 1.1)
- People whose situation meets the South Korean national health insurance criteria for coverage of a type of scan called F-18 FDG PET-CT, used to check how well treatment is working (confirm with trial site)
- People who are about to begin their first main treatment for advanced breast cancer — such as hormone therapy, targeted therapy, chemotherapy, immunotherapy, or a combination of these
- People who are willing to have regular scans (F-18 FDG PET-CT and contrast-enhanced CT, and possibly bone scans if clinically needed) at set time points — before treatment starts and at 6, 12, 24, and 48 weeks after treatment begins — and who are prepared to cover the cost of these scans as required
- People with a general health and activity level that falls within a standard research scoring range of 0 to 2 (meaning able to carry out daily activities, with at most some limitations) (confirm with trial site)
Who may not be able to join:
- People who have previously received systemic treatment (such as chemotherapy or hormone therapy) for advanced breast cancer
- People for whom the F-18 FDG PET-CT scan is not safe — for example, those with uncontrolled diabetes — or for whom the contrast dye used in CT scans is not safe — for example, those with severe allergies or serious kidney problems
- People who are pregnant or currently breastfeeding
- People who have another active primary cancer at the same time, unless treatment for that other cancer has already been fully completed with the aim of curing it
- People with other health conditions that the treating doctor believes could interfere with taking part in the study or make it harder to interpret the results
- People who are unable to follow the study procedures or attend the required follow-up visits
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +82-2-3410-1780
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Follow up the response for 48 weeks after the start of the first systemic treatment
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.